Medical Marijuana: Global Cannabis Applications is asking the right questions

In the movie Medicine Man (1992) Sean Connery plays a medical botanist working deep in the Amazon rain forest who discovers the cure for cancer only to lose it again because he was not able to find the source of the crucial components of the test serum. As a physician treating all manner of trauma and chronic pain (the real plague of the 21st century!) with cannabinoid compounds I have often asked myself how often something just like that actually occurs. I don’t mean anything quite so dramatic as the cure for cancer, PTSD or chronic pain but something more subtle and lost in the noise.

Imagine the true complexity of prescribing full-spectrum cannabis for a poorly defined syndrome such as PTSD. The patient has their own unique baseline chemical phenotype, heterogeneity of their endocannabinoid system, time-varying neurohumoral variances, as well differences in attitude, diet, toxin exposure and social support (and this is all before the traumatic event).

How many 4-space variables is that per unit time? Millions? Let’s continue. How many active components are present in whole cannabis? Hundreds. How do these components interact with each other and the totality of the patient? Entourage Effect? Are you kidding me?!

By the way, which cannabis strain are we talking about? Which batch number (if there is one)? What soil, which grower, what additives, any pesticides? Now let’s change the delivery system from oral (passing through the hostile acidic domain of the stomach to the metabolic computer known as the liver) to incinerated and inhaled (are the active components still present and active? active in the same way?).

Perhaps lost in all the resultant complexity is the one dose, of the one cannabis strain, at the one time, under the one set of chemical conditions that actually made a (repeatable) difference to the patient. Maybe we lose the effective treatment for PTSD every day. How would we ever know?

The answer lies in how we ask the questions.

The legalization of cannabis in Canada (and soon the world) finally brought something huge out of the dark and into the light of medical oversight. Canada has assembled superb usage guidelines, information-gathering tools, best medical practice guidelines, public health reporting systems, effective public education systems and a regulatory framework guided by rational science-based goals. The symphony is assembled on stage and the conductor stands ready. We await only the appearance of the first violin and that perfect middle-C note to tune the mob.

Without effective, stable and verifiable baseline medical cannabis strains, the symphony will never be in tune.

CEO Bradley Moore (Canadian military veteran and cancer survivor) and his team at Global Cannabis Applications Corporation (GCAC) are asking exactly the right questions and have built a blockchain-powered AI system capable of giving us the answers. The patented system is embedded in the apps Efixii and Prescriptii and if you are a medical cannabis user (or grower) you should download them now.

Strain Insider asked GCAC to frame the problem for us and help us understand the solutions.

The interview

Strain Insider: What is the basic problem facing medical cannabis users?

Bradley Moore: “Marijuana is used for treating chronic pain that affects millions of people each year across the globe. Demand for medical cannabis globally is growing rapidly and is estimated to reach USD 148 Billion by 2026 in Canada, US and the EU. The big problem for medical cannabis is that the clinical product tested is not always the same as the product sold to consumers. Why? Cannabis is a complex plant that is evolving until it is consumed. GCAC’s patented Citizen Green technology was developed to ensure a stable and verifiable information loop from cultivator to medical consumer”.

“We need better solutions for chronic pain. This means we need better data and consistent medical cannabis strains”

Strain Insider: How do we ensure cannabis is an effective treatment for chronic pain?

Bradley Moore: “If cannabis is going to regain its place as a legitimate medical tool we need to have the data. We also need verifiable stability, look-back ability and effective medical strain definitions and baselines. All of this means data, data and more data! The problem is huge. There are at least 9000 recreational cannabis strains for sale and at least 564 designated medical strains globally. In the UK alone there are over 20,000 patients being supplied medical cannabis under the Project Twenty21 Medical Cannabis Program. Globally there are no less than 17 formal clinical trials actively investigating medical cannabis efficacy and this number is growing rapidly as countries proceed through decriminalization in all forms. Medical informatics companies are desperate for more data with a minimum 23.2% CAGR growth rate for global medical analytics projecting a market value of USD $12.1 billion by 2024.”

“Cannabis is a complex time-varying data problem”

Strain Insider: How can GCAC help the cannabis industry achieve product consistency?

Bradley Moore: “Without product consistency, medical consumers see little value in current cannabis brands since they have no way of knowing what they are taking and no way of ensuring they can purchase the same product again. GCAC’s patent creates this value for consumers, cultivators, retailers, medical professionals and regulators. GCAC’s patent is defined “as the process for determining the averaged efficacy of a consumed gram of medical cannabis (or CBD) for the treatment of a specific ailment through the use of an Artificial Intelligence algorithm, which is then stored on an immutable blockchain with the specific growing data of that gram”. The consumer is assured of knowing what they have taken and the chain can be followed all the way back to the seed helping physicians and researchers isolate the critical chemical components.”

“Any drug used for a medical purpose must be fully defined and stable. The condition the drug is being used for must also be defined. The problem with cannabis is that these definitions either don’t exist or are changing with every new gram of cannabis and patients don’t even know what they are taking!”

Strain Insider: How does blockchain assist producers and consumers?

Bradley Moore: “Blockchain-powered Efixii is the only system to provide a consumer data feedback per product to the grower building a stronger and longer-lasting relationship. Efixii attests all steps of cultivation onto a blockchain, creates a specific QR code label for EACH individual product and enables a consumer to scan the QR into their Efixii app. The consumer then easily records their individual clinical experience. The Efixii data can be easily scaled to meet the needs of any patient, physician or even a national level clinical trial….all the way back to when the cannabis seed was first placed in the soil!”

Strain Insider: How does the Prescriptii app help physicians and patients choose the correct cannabis products?

Bradley Moore: “The same principles are at work in our Prescriptii app. The Prescriptii platform is built on an advanced algorithm that analyzed over 600,000 verified data of 9,000 strains for more than 80 medical conditions. Using machine learning, Prescriptii then established links between the conditions and strains to create a data-driven picture of medical cannabis. Using Prescriptii a physician or patient can easily search for strains with known benefits that match the condition to power better decision making”.

“Pain to Strain, Strain to Pain and Strain to Strain….its all in the data”

Strain Insider: How will GCAC help industry fine-tune the best medical cannabis strains?

Bradley Moore: “The potential for this technology really can’t be understated and may in fact represent a “medical standard of care” for clinical cannabis usage. Wide-scale adoption by consumers will only make the data better both for detecting the critical effective composition of any given strain but also those components giving rise to adverse outcomes and side effects. Once we have found the right strains we also need to ensure their longevity given the natural tendency for strains to drift. This technology solves all of these problems in one app”.

“Presciptii and Efixii may represent a new medical standard of care for medical cannabis users and prescribers.”

Strain Insider: Can blockchain offer benefits beyond strain consistency and medical decision making?

Bradley Moore: “Blockchain has the power to track literally any aspect of the cannabis industry. With increasing global pressure to achieve environmental consciousness our system will assist cannabis producers and regulators to achieve carbon neutrality.”

The bottom line

So who bears the ultimate responsibility for the composition of so-called “medical cannabis strains”. Is this something we leave in the hands of cannabis companies intent on sales charts and the next greatest cannabis product? Gone is the mild (and probably only true medicinal strain) cannabis your parents’ parents got-silly-with only to be replaced with the awesome industrial power of the latest giga-THC strain.

It would serve us well to be mindful of what we are referring to when we say “cannabis”, which now refers to an evolving family of bioengineered whole and component phytobotanicals. Perhaps more important to realize is that as of today your budtender’s menu is the same menu from which your physician makes your medical recommendations (better hurry the dishes change without notice).

“Primordial cannabis is to the cannabis strains of today as wild tobacco is to a cigarette”.

It shouldn’t be this way and it clearly doesn’t have to be. The first violin of Bradley Moore and GCAC has finally appeared on stage and is sounding a perfect middle-C. With data-driven rational medical decision-making replacing the out-of-tune chaos of the mob GCAC is providing the badly needed leadership needed to achieve effective, safe and standardized medical cannabis strains. Strain Insider looks forward to a better future!

Leave a Reply

Your email address will not be published.